Just won an award.....very Isable..(if you can put it that way)..another of Robbie Burns clever stock picks....decided myself to join in...not sure how high this could go but looking good at the moment !.

Just about breaking out.

OPTS OPTUS

Some lofty Broker SP targets for
this company......

Date Company Name Broker Rec. Price Old target price New target price Notes

15 Oct Optos PLC Canaccord Genuity Buy 212.50 306.00 306.00 Retains
15 Oct Optos PLC Investec Hold 212.50 202.00 202.00 Retains
15 Oct Optos PLC Numis Buy 212.50 300.00 300.00 Reiterates
15 Oct Optos PLC Panmure Gordon Buy 212.50 230.00 320.00 Upgrades
15 Oct Optos PLC Jefferies International Buy 212.50 270.00 280.00 Retains

NORWICH & PETERBOROUGH BUILDING SOCIETY

I'm in GF despite the spread.

Plenty left in this one Chris. Technology is out on its own. Biggest chunk of stock ive held for months.

Agree mate I've bought a few for long term.

A p/e of 12 plus, blimey Ive seen these type of medical tech stocks with P/es of 50 plus to 75 or more.

OPTOS OPTS


Fallen back a little bit on
intraday chart usually comes
with a big run to day end....

Brokers like it.....

Optos PLC
FORECASTS 2012 2013

Date Rec Pre-tax (£) EPS (p) DPS (p) Pre-tax (£) EPS (p) DPS (p)
Panmure Gordon
19-10-12 BUY 16.27 17.58 22.24 23.97
Peel Hunt
17-10-12 HOLD 13.74 13.38 9.22 8.99
Numis Securities Ltd
15-10-12 BUY 15.04 14.17 16.22 14.73
Canaccord Genuity Ltd
15-10-12 BUY 15.09 14.13 20.29 19.91
Shore Capital
12-10-12 HOLD 15.60 15.14 18.50 17.98
Investec Securities
05-10-12 HOLD 14.68 13.12 16.62 15.62
N+1 Singer
25-09-12 BUY 17.74 17.72 19.36 18.86
Nomura Code
02-08-12 BUY 11.51 10.94 17.33 16.44

2012 2013
Pre-tax (£) EPS (p) DPS (p) Pre-tax (£) EPS (p) DPS (p)

Consensus 15.21 14.82 17.37 17.03
1 Month Change 0.52 0.47 -0.73 -0.59
3 Month Change 1.08 1.16 -0.28 -0.06


GROWTH
2011 (A) 2012 (E) 2013 (E)

Norm. EPS 114.56% -57.00% 14.86%
DPS % % %

INVESTMENT RATIOS
2011 (A) 2012 (E) 2013 (E)

EBITDA £41.34m £30.66m £29.29m
EBIT £25.36m £15.28m £17.18m
Dividend Yield % % %
Dividend Cover x x x
PER 6.02x 14.00x 12.19x
PEG 0.05f -0.25f 0.82f
Net Asset Value PS 64.56p 95.47p 110.82p

A few days historical.

http://www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=20427759 http://www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=20427759

Worth a read.....

http://www.bbc.co.uk/news/uk-scotland-scotland-business-19949157

A buy in this weeks shares publication. The retinal diagnostics specialist has boosted sales by 32% this year. Now with the US market accounting for 80% of sales of its new Daytona scanning machine, expect more growth.

Notice of Results
RNS
RNS Number : 6922P
Optos plc
29 October 2012









OPTOS PLC



NOTICE OF PRELIMINARY RESULTS





LONDON, UK, 29 October 2012 - Optos plc (LSE: OPTS) the leading retinal imaging company, will announce its preliminary results for the year ended 30 September 2012 on Wednesday, 21 November 2012.



A presentation for analysts will be held at 9.30am at the offices of FTI Consulting, Holborn Gate, 26 Southampton Buildings, London WC2A 1PB.





Enquiries:



FTI Consulting
Tel: +44 (0) 20 7831 3113

Mo Noonan

OPTS OPTOS

Brokers have certainly got very
bullish SP targets in place

Optos Broker Views

Date Broker Recommendation Price Old target price New target price Notes

15 Oct Canaccord Genuity Buy 181.50 306.00 306.00 Retains
15 Oct Investec Hold 181.50 202.00 202.00 Retains
15 Oct Numis Buy 181.50 300.00 300.00 Reiterates
15 Oct Panmure Gordon Buy 181.50 230.00 320.00 Upgrades
15 Oct Jefferies International Buy 181.50 270.00 280.00 Retains

NORWICH & PETERBOROUGH BUILDING SOCIETY

And we can see from hemscott
the P/E is hardly demanding going forward....

INVESTMENT RATIOS
2011 (A) 2012 (E) 2013 (E)

EBITDA £41.34m £29.40m £27.55m
EBIT £25.36m £14.77m £17.37m
Dividend Yield % % %
Dividend Cover x x x
PER 5.08x 12.64x 10.44x
PEG 0.04f -0.21f 0.50f
Net Asset Value PS 64.56p 68.58p 82.16p

Results wed coming.

Worth having a look at this historical link...

http://www.thisismoney.co.uk/money/investing/article-2220663/MIDAS-SHARE-TIPS-Great-outlook-eye-imaging-firm-Optos.html

OPTS OPTOS

TECHINVEST.......

I noticed in the free jul issue of techinvest that they made this a nap tip for 2nd part of the year at.......

190p expressing "no clear reasons why the price has underperformed recently". They also bought it into their portfolio at 230p in may12.

OPTS OPTOS

Just a reminder of the last trading
statement........

OPTOS PLC

TRADING UPDATE
15/oct 2012


Daytona Delivers



LONDON, UK, 15 October 2012 - Optos plc (LSE: OPTS), the leading medical retinal imaging company, today provides a trading update for the financial year ended 30 September 2012, ahead of the planned publication of its Preliminary Results on 21 November 2012. All figures are unaudited.



Following strong sales in the last quarter, revenues for the year to 30 September 2012 are expected to exceed $190m, ahead of market expectations.

http://www.investegate.co.uk/optos-plc-(opts)/rns/trading-statement/201210150700066486O/

OPT OPTOS

Just out....

16 Nov Optos PLC OPTS Panmure Gordon Buy 185.75 184.75 320.00 320.00 Retains

SP TARGET a whopping 320p.

OPT OPTOS

just out another reco

16 Nov Optos PLC OPTS Jefferies International Buy 185.50 184.75 280.00 280.00 Retains

280p SP Tatget.

Historical item on OPTS

http://www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=20441825

OPT OPTOS

Remember results wed.

Article linked to them below.


Strong end to the year for Optos
Mon 15 Oct 2012

OPTS - Optos

Latest Prices
Name Price %
Optos 179.50p -2.84%

FTSE All-Share 2,940 -0.98%
FTSE Small Cap 3,186 -0.79%
techMARK 2,024 -0.87%
techMARK 100 2,351 -0.65%
Health Care Equipment & Services 3,634 -0.77%

LONDON (SHARECAST) - Optos saw shares rise strongly on Monday morning after saying that both turnover and operating profit for the year ending September 30th was ahead of market expectations.

The ophthalmology equipment maker reported that, following strong sales in the last quarter, “revenues are expected to exceed $190m”, ahead of consenus expectations of $183m, with operating profit expected to be “slightly above market consensus” of $22.3m.

Manufacture of its latest product range, the Daytona, has reached current planned capacity in the last quarter, allowing the full year (ending 2012) order backlog to be fully cleared and resulting in an installed base of 329 devices at the end of September 2012.

As stated in its third-quarter interim management statement, the company expects “gross margins to improve during full year 2013 as Daytona volumes increase”.

Chief Executive Officer Roy Davis commented: “I am delighted with the company’s achievements this year and in particular, the manufacturing scale-up and market roll-out of Daytona.

"The reaction to this instrument has been very positive and I am excited by the opportunities it brings to the business. Our near-term focus is to drive sales of Daytona in all our key markets and to continue our success with the 200Tx instrument in the ophthalmology market.”


Broker reaction


Broker reaction to the update has been equally positive. Numis has reiterated its “buy” rating and 300p share price target, while Jefferies, which also has a “buy” rating, has raised its price target to 280p from 270p.

Meanwhile, Panmure Gordon has upgraded its rating from 'hold' to 'buy', saying that Optos "should be a core holding to investors looking to have healthcare in their portfolio". The broker raised its target price for the shares from 230p to 320p.

http://www.sharecast.com/cgi-bin/sharecast/story.cgi?story_id=20427759